Quentis Therapeutics

2018’s Fierce 15 on biotech investment and the next decade

This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.

Conor Hale , Amirah Al Idrus Oct 3, 2018 11:06am